A double-blind, randomized, placebo and active-controlled, six-period crossover study to evaluate the likeability, safety, and abuse liability of NRP104 [lisdexamfetamine] in healthy adult volunteers with histories of stimulant abuse

Trial Profile

A double-blind, randomized, placebo and active-controlled, six-period crossover study to evaluate the likeability, safety, and abuse liability of NRP104 [lisdexamfetamine] in healthy adult volunteers with histories of stimulant abuse

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Jun 2009

At a glance

  • Drugs Amfepramone; Amfetamine; Lisdexamfetamine
  • Indications Attention-deficit hyperactivity disorder
  • Focus Pharmacodynamics
  • Sponsors New River Pharmaceuticals
  • Most Recent Events

    • 21 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top